Compare Stocks: LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GH Guardant Health	$157.88 -0.5%	$167.94	$65.96 ▼ $191.05	$21.19B	1.58	2.21 million shs	1.87 million shs
ILMN Illumina	$262.66 +0.0%	$234.53	$94.00 ▼ $309.35	$39.66B	1.41	2.18 million shs	1.90 million shs
LLY Eli Lilly and Company	$1,242.76 -1.1%	$1,180.08	$793.82 ▼ $1,292.65	$1.17T	0.46	2.95 million shs	1.96 million shs
MDT Medtronic	$92.83 -2.0%	$91.03	$73.31 ▼ $106.33	$118.75B	0.55	11.44 million shs	23.01 million shs
MRK Merck & Co., Inc.	$143.58 -1.6%	$145.60	$82.01 ▼ $156.92	$354.24B	0.21	10.64 million shs	10.45 million shs
MRNA Moderna	$226.89 +4.1%	$156.66	$22.28 ▼ $242.29	$90.58B	1.09	12.38 million shs	18.77 million shs
TEM Tempus AI	$64.34 -0.6%	$68.07	$40.77 ▼ $96.29	$11.61B	3.54	6.22 million shs	4.17 million shs
UNH UnitedHealth Group	$406.99 +1.4%	$387.07	$255.96 ▼ $461.62	$365.31B	0.6	7.39 million shs	4.99 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GH Guardant Health	0.00%	-5.30%	-11.58%	+7.11%	+142.29%
ILMN Illumina	0.00%	-5.62%	+9.57%	+42.16%	+175.03%
LLY Eli Lilly and Company	0.00%	+6.83%	+9.15%	+9.69%	+56.56%
MDT Medtronic	0.00%	+7.03%	+2.82%	+13.81%	-0.87%
MRK Merck & Co., Inc.	0.00%	+0.33%	-0.35%	+17.36%	+72.22%
MRNA Moderna	0.00%	-3.11%	+41.54%	+266.46%	+738.18%
TEM Tempus AI	0.00%	-8.76%	-16.86%	+33.69%	-26.27%
UNH UnitedHealth Group	0.00%	+6.06%	+6.55%	-4.76%	+12.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GH Guardant Health	$157.88 -0.5%	$167.94	$65.96 ▼ $191.05	$21.19B	1.58	2.21 million shs	1.87 million shs
ILMN Illumina	$262.66 +0.0%	$234.53	$94.00 ▼ $309.35	$39.66B	1.41	2.18 million shs	1.90 million shs
LLY Eli Lilly and Company	$1,242.76 -1.1%	$1,180.08	$793.82 ▼ $1,292.65	$1.17T	0.46	2.95 million shs	1.96 million shs
MDT Medtronic	$92.83 -2.0%	$91.03	$73.31 ▼ $106.33	$118.75B	0.55	11.44 million shs	23.01 million shs
MRK Merck & Co., Inc.	$143.58 -1.6%	$145.60	$82.01 ▼ $156.92	$354.24B	0.21	10.64 million shs	10.45 million shs
MRNA Moderna	$226.89 +4.1%	$156.66	$22.28 ▼ $242.29	$90.58B	1.09	12.38 million shs	18.77 million shs
TEM Tempus AI	$64.34 -0.6%	$68.07	$40.77 ▼ $96.29	$11.61B	3.54	6.22 million shs	4.17 million shs
UNH UnitedHealth Group	$406.99 +1.4%	$387.07	$255.96 ▼ $461.62	$365.31B	0.6	7.39 million shs	4.99 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GH Guardant Health	0.00%	-5.30%	-11.58%	+7.11%	+142.29%
ILMN Illumina	0.00%	-5.62%	+9.57%	+42.16%	+175.03%
LLY Eli Lilly and Company	0.00%	+6.83%	+9.15%	+9.69%	+56.56%
MDT Medtronic	0.00%	+7.03%	+2.82%	+13.81%	-0.87%
MRK Merck & Co., Inc.	0.00%	+0.33%	-0.35%	+17.36%	+72.22%
MRNA Moderna	0.00%	-3.11%	+41.54%	+266.46%	+738.18%
TEM Tempus AI	0.00%	-8.76%	-16.86%	+33.69%	-26.27%
UNH UnitedHealth Group	0.00%	+6.06%	+6.55%	-4.76%	+12.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GH Guardant Health	2.96	Moderate Buy	$190.00	20.34% Upside
ILMN Illumina	2.44	Hold	$231.88	-11.72% Downside
LLY Eli Lilly and Company	2.86	Moderate Buy	$1,313.43	5.69% Upside
MDT Medtronic	2.57	Moderate Buy	$102.88	10.82% Upside
MRK Merck & Co., Inc.	2.63	Moderate Buy	$151.92	5.81% Upside
MRNA Moderna	2.12	Hold	$101.45	-55.29% Downside
TEM Tempus AI	2.41	Hold	$72.37	12.48% Upside
UNH UnitedHealth Group	2.71	Moderate Buy	$462.90	13.74% Upside

Current Analyst Ratings Breakdown

Latest LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	ILMN Illumina	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Hold	$205.00 ➝ $300.00
10/16/2026	UNH UnitedHealth Group	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$500.00
10/16/2026	UNH UnitedHealth Group	Stephens Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$500.00
10/16/2026	UNH UnitedHealth Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$516.00 ➝ $524.00
10/15/2026	GH Guardant Health	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B) ➝ Buy (B+)
10/15/2026	UNH UnitedHealth Group	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$450.00
10/15/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$120.00 ➝ $137.00
10/15/2026	UNH UnitedHealth Group	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold	$402.00
10/14/2026	MDT Medtronic	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral
10/14/2026	MDT Medtronic	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Cautious

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GH Guardant Health	$982.02M	21.58	N/A	N/A	($0.79) per share	-199.85
ILMN Illumina	$4.34B	9.13	$6.72 per share	39.10	$17.82 per share	14.74
LLY Eli Lilly and Company	$79.67B	14.68	$24.85 per share	50.01	$28.07 per share	44.27
MDT Medtronic	$37.54B	3.16	$7.69 per share	12.07	$39.00 per share	2.38
MRK Merck & Co., Inc.	$65.01B	5.45	$11.23 per share	12.78	$21.22 per share	6.77
MRNA Moderna	$1.94B	46.60	N/A	N/A	$22.14 per share	10.25
TEM Tempus AI	$1.43B	8.11	N/A	N/A	$2.76 per share	23.31
UNH UnitedHealth Group	$450.13B	0.81	$21.56 per share	18.88	$110.49 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GH Guardant Health	-$416.28M	-$3.49	N/A	N/A	N/A	-38.33%	N/A	-25.40%	11/5/2026 (Confirmed)
ILMN Illumina	$850M	$5.36	49.00	42.92	3.72	18.36%	29.84%	12.17%	10/29/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	41.70	26.34	1.67	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
MDT Medtronic	$4.80B	$4.06	22.87	14.60	2.16	13.93%	14.78%	7.97%	11/17/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	114.86	15.49	6.74	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/6/2026 (Estimated)
TEM Tempus AI	-$245.03M	-$1.44	N/A	N/A	N/A	-17.77%	-50.28%	-10.33%	11/2/2026 (Confirmed)
UNH UnitedHealth Group	$12.06B	$17.51	23.24	17.65	1.45	3.53%	17.95%	5.95%	N/A

Latest LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	MRNA Moderna	-$1.09	N/A	N/A	N/A	$892.41 million	N/A
11/5/2026	Q3 2026	GH Guardant Health	-$0.7526	N/A	N/A	N/A	$350.76 million	N/A
11/2/2026	Q3 2026	TEM Tempus AI	-$0.0751	N/A	N/A	N/A	$409.39 million	N/A
10/29/2026	Q3 2026	ILMN Illumina	$1.36	N/A	N/A	N/A	$1.15 billion	N/A
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$5.65	N/A	N/A	N/A	$22.47 billion	N/A
10/29/2026	Q3 2026	MRK Merck & Co., Inc.	$2.09	N/A	N/A	N/A	$17.29 billion	N/A
10/13/2026	Q3 2026	UNH UnitedHealth Group	$4.14	$4.69	+$0.55	$4.56	$111.31 billion	$112.70 billion
9/1/2026	Q1 2027	MDT Medtronic	$1.39	$1.45	+$0.06	$1.14	$9.55 billion	$9.76 billion
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.55%	+15.18%	23.22%	11 Years
MDT Medtronic	$2.88	3.08%	+4.13%	70.94%	49 Years
MRK Merck & Co., Inc.	$3.40	2.33%	+5.75%	272.00%	14 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
TEM Tempus AI	N/A	N/A	N/A	N/A	N/A
UNH UnitedHealth Group	$9.28	2.30%	+12.57%	53.00%	15 Years

Latest LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/20/2026	MDT Medtronic	quarterly	$0.72	3.26%	9/25/2026	9/25/2026	10/16/2026
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.36%	9/15/2026	9/15/2026	10/7/2026
8/11/2026	UNH UnitedHealth Group	quarterly	$2.32	2.42%	9/14/2026	9/14/2026	9/22/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GH Guardant Health	N/A	4.03	3.71
ILMN Illumina	0.53	1.80	1.40
LLY Eli Lilly and Company	1.41	1.35	1.00
MDT Medtronic	0.50	2.07	1.54
MRK Merck & Co., Inc.	1.22	1.32	1.10
MRNA Moderna	0.09	2.29	2.18
TEM Tempus AI	3.06	3.30	3.16
UNH UnitedHealth Group	0.66	0.74	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GH Guardant Health	92.60%
ILMN Illumina	89.42%
LLY Eli Lilly and Company	82.53%
MDT Medtronic	82.06%
MRK Merck & Co., Inc.	76.07%
MRNA Moderna	75.33%
TEM Tempus AI	24.22%
UNH UnitedHealth Group	87.86%

Insider Ownership

Company	Insider Ownership
GH Guardant Health	5.60%
ILMN Illumina	2.90%
LLY Eli Lilly and Company	0.14%
MDT Medtronic	0.27%
MRK Merck & Co., Inc.	0.17%
MRNA Moderna	10.80%
TEM Tempus AI	24.26%
UNH UnitedHealth Group	0.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GH Guardant Health	2,506	134.20 million	126.68 million	Not Optionable
ILMN Illumina	8,650	151.00 million	146.62 million	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
TEM Tempus AI	3,800	180.44 million	136.66 million	N/A
UNH UnitedHealth Group	390,000	897.60 million	895.89 million	Optionable

LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Headlines

Recent News About These Companies

4.6 Million Americans Leave Health Insurance Market in Biggest Exodus in a Decade — and Those Staying Face a 15% Rate Hike

3 hours ago | 247wallst.com

UnitedHealth Group (UNH) Has The Market Asking A Bigger Question

3 hours ago | finance.yahoo.com

2,646 UnitedHealth Group Incorporated $UNH Shares Acquired by BDF Gestion

4 hours ago | marketbeat.com

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning (UNH)

...

October 19 at 10:30 AM | marketbeat.com

4.6 Million Americans Leave Health Insurance Market in Biggest Exodus in a Decade — and Those Staying Face a 15% Rate Hike

October 19 at 9:42 AM | 247wallst.com

Healthcare ETFs to Buy as UnitedHealth Beats on Q3 Earnings

October 19 at 9:26 AM | zacks.com

3.2 Million Seniors Will Lose Their Medicare Advantage Plans in 2027 — and Their Replacement Options Are Shrinking

October 19 at 9:14 AM | 247wallst.com

Is UnitedHealth Group Stock a Buy After Another Solid Quarter?

October 19 at 8:30 AM | fool.com

UnitedHealth: My Thesis Has Played Out, I Wouldn't Chase Here (Rating Downgrade)

October 19 at 8:00 AM | seekingalpha.com

Is UnitedHealth Group Stock a Buy After Another Solid Quarter?

October 19 at 8:00 AM | fool.com

What a Mixed Midterm Result Could Mean for These 2 Health Care ETFs (UNH)

...

October 19 at 7:30 AM | marketbeat.com

SteelPeak Wealth LLC Acquires 13,533 Shares of UnitedHealth Group Incorporated $UNH

October 18 at 5:51 AM | marketbeat.com

UnitedHealth Group Incorporated $UNH Stock Position Lowered by IFP Advisors Inc

October 18 at 5:51 AM | marketbeat.com

PineStone Asset Management Inc. Acquires 20,800 Shares of UnitedHealth Group Incorporated $UNH

October 18 at 5:35 AM | marketbeat.com

5,184 Shares of UnitedHealth Group Incorporated $UNH Acquired by Encompass More Asset Management

October 18 at 4:07 AM | marketbeat.com

UnitedHealth Group (NYSE:UNH) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

October 18 at 2:44 AM | americanbankingnews.com

UnitedHealth: 3 Key Takeaways for Long-Term Investors

October 17 at 3:00 PM | fool.com

UnitedHealth Group Incorporated $UNH Stake Boosted by TD Waterhouse Canada Inc.

October 17 at 12:08 PM | marketbeat.com

UnitedHealth Group Incorporated $UNH Holdings Boosted by Annex Advisory Services LLC

October 17 at 3:11 AM | marketbeat.com

UnitedHealth: Q3 Confirms The Bull Case

October 16 at 11:00 PM | seekingalpha.com

Where Could UnitedHealth's Next Growth Come From?

October 16 at 2:24 PM | trefis.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Company Descriptions

Guardant Health NASDAQ:GH

$157.88 -0.72 (-0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$158.16 +0.28 (+0.18%)

As of 04:17 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Illumina NASDAQ:ILMN

$262.66 +0.12 (+0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$270.32 +7.66 (+2.92%)

As of 05:28 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Eli Lilly and Company NYSE:LLY

$1,242.76 -14.27 (-1.14%)

Closing price 03:59 PM Eastern

Extended Trading

$1,242.01 -0.75 (-0.06%)

As of 05:28 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic NYSE:MDT

$92.83 -1.92 (-2.02%)

Closing price 03:59 PM Eastern

Extended Trading

$92.92 +0.09 (+0.09%)

As of 05:24 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Merck & Co., Inc. NYSE:MRK

$143.58 -2.37 (-1.62%)

Closing price 03:59 PM Eastern

Extended Trading

$143.88 +0.30 (+0.21%)

As of 05:24 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna NASDAQ:MRNA

$226.89 +8.88 (+4.07%)

Closing price 04:00 PM Eastern

Extended Trading

$227.62 +0.73 (+0.32%)

As of 05:28 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Tempus AI NASDAQ:TEM

$64.34 -0.38 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$64.45 +0.11 (+0.17%)

As of 05:26 PM Eastern

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

UnitedHealth Group NYSE:UNH

$406.99 +5.56 (+1.39%)

Closing price 03:59 PM Eastern

Extended Trading

$406.78 -0.21 (-0.05%)

As of 05:28 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Earnings

Compare Dividends

Latest LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, MRNA, MRK, GH, ILMN, TEM, MDT, and UNH Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools